HCPCS Level II · Miscellaneous services (temporary codes)
Q9989Ustekinumab, for intravenous injection, 1 mg
Terminated 12/31/2017
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About Q9989
Q9989 is an HCPCS Level II code in the Q series (miscellaneous services (temporary codes)), describing ustekinumab, for intravenous injection, 1 mg.
It was added to HCPCS effective 07/01/2017, and its current record took effect 01/01/2018.
It was terminated on 12/31/2017 and can't be billed for later dates of service.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Ustekinumab, iv inject,1 mg
- Date added
- 07/01/2017
- Action effective
- 01/01/2018
- Termination date
- 12/31/2017
- BETOS
- O1E
Related Q99xx codes
- Q9950Injection, sulfur hexafluoride lipid microspheres, per ml
- Q9951Low osmolar contrast material, 400 or greater mg/ml iodine concentration, per ml
- Q9953Injection, iron-based magnetic resonance contrast agent, per ml
- Q9954Oral magnetic resonance contrast agent, per 100 ml
- Q9955Injection, perflexane lipid microspheres, per ml
- Q9956Injection, octafluoropropane microspheres, per ml
- Q9957Injection, perflutren lipid microspheres, per ml
- Q9958High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml
- Q9959High osmolar contrast material, 150-199 mg/ml iodine concentration, per ml
- Q9960High osmolar contrast material, 200-249 mg/ml iodine concentration, per ml
- Q9961High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml
- Q9962High osmolar contrast material, 300-349 mg/ml iodine concentration, per ml
Common questions about Q9989
Is HCPCS Q9989 still valid?
- No. Q9989 was terminated on 12/31/2017.
Does Medicare cover Q9989?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.